Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;24(5):1312-1333.
doi: 10.1007/s10461-019-02733-z.

The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review

Jennifer L Glick  1   2 , Rienna Russo  3 , Belinda Jivapong  4 , Lori Rosman  5 , Danielle Pelaez  6 , Katherine H A Footer  6 , Susan G Sherman  6
Affiliations

The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review

Jennifer L Glick et al. AIDS Behav. 2020 May.

Abstract
in English, Spanish

HIV prevalence among cisgender female sex workers (FSW) and/or women who use drugs (WWUD) is substantially higher compared to similarly aged women. Consistent with PRISMA guidelines, we conducted the first systematic review on the pre-exposure prophylaxis (PrEP) continuum among FSW and/or WWUD, searching PubMed, Embase, CINAHL, PsycInfo, and Sociological Abstracts. Eligibility criteria included: reporting a PrEP related result among FSW and/or WWUD aged 18 + ; peer-reviewed; and published in English between 2012 and 2018. Our search identified 1365 studies; 26 met eligibility requirements, across the following groups: FSW (n = 14), WWUD (n = 9) and FSW-WWUD (n = 3). Studies report on at least one PrEP outcome: awareness (n = 12), acceptability (n = 16), uptake (n = 4), and adherence (n = 8). Specific barriers span individual and structural levels and include challenges to daily adherence, cost, and stigma. Combining health services and long-acting PrEP formulas may facilitate better PrEP uptake and adherence. The limited number of studies indicates a need for more research.

La prevalencia del VIH es sustancialmente mayor entre trabajadoras sexuales cisgénero (FSW) y/o mujeres que usan drogas (WWUD) en comparación con mujeres de edad similar. Siguiendo PRISMA, realizamos la primera revisión sistemática sobre el continuo de la Profilaxis Preexposición (PrEP) entre estos grupos. Los criterios de elegibilidad fueron: informar un resultado de PrEP entre FSWs y/o WWUDs con mayores de edad; que haya pasado por revisión de pares; y publicados en inglés entre el 2012 y el 2018. Identificamos 1,365 estudios; 26 cumplieron los criterios: FSW (n=14), WWUD (n=9) y FSW-WWUD (n=3). Los estudios nos informaron sobre: conocimiento (n=12), aceptabilidad (n=16), uso, (n=4) y adherencia (n=8). Las barreras incluyen la adherencia, el costo, y el estigma. La combinación de los servicios de salud y de PrEP de acción-prolongada pueden facilitar mejor uso y adherencia a la PrEP. El número limitado de estudios indica la necesidad de más investigación.

Keywords: Female sex workers (FSW); Global; PrEP care continuum; Pre-exposure prophylaxis (PrEP); Systematic review; Women who use drugs (WWUD).

PubMed Disclaimer

Conflict of interest statement

Competing interests

We declare no competing interests.

Figures

Figure 1:
Figure 1:
PRISMA Flow Diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baral S, Beyrer C, Muessig K, Poteat T, Wirtz AL, Decker MR, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet infectious diseases. 2012;12(7):538–49. - PubMed
    1. Larney S, Mathers BM, Poteat T, Kamarulzaman A, Degenhardt L. Global epidemiology of HIV among women and girls who use or inject drugs: current knowledge and limitations of existing data. Journal of acquired immune deficiency syndromes (1999). 2015;69(Suppl 2):S100. - PMC - PubMed
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90. - PubMed
    1. Organization WH. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). 2015.
    1. Cleland CM, Des Jarlais DC, Perlis TE, Stimson G, Poznyak V. HIV risk behaviors among female IDUs in developing and transitional countries. BMC public health. 2007;7(1):271. - PMC - PubMed

Publication types

Substances